Drug intelligence / Profile preview

AMG 114

Development stage: Phase 2
Lead developer: Amgen
Modality: Recombinant Proteins and Enzymes
Administration: Intravenous, Subcutaneous

Overview

AMG 114 is a novel, hyperglycosylated erythropoiesis-stimulating agent developed for the treatment of anemia associated with chemotherapy in patients with non-myeloid malignancies. It was designed to have increased potency and a longer half-life compared to existing agents such as darbepoetin alfa and epoetin alfa. In clinical studies, AMG 114 demonstrated dose-proportional pharmacokinetics and was generally well tolerated, but development was halted due to modest efficacy[1][2]. The mechanism of action is as an agonist of the erythropoietin receptor. It was developed by Amgen.

Targets

Erythropoietin Receptor

Beyond the preview

Go deeper on AMG 114.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AMG 114.

Explore the full profile